London Genetics Limited, an expert in the use of pharmacogenetics in clinical drug discovery and development, has entered an intensive partnering programme following on from its successful pharmacogenetic conference in September. The meeting recognised that while pharmacogenetics and genetics have great potential in helping the biopharmaceutical industry overcome its many challenges, early clinical collaboration between companies, academia, regulators and payers is now needed.
The company will over the coming months be attending several conferences in the UK, Europe and the US to highlight its pharmacogenetics expertise. These include in November Bio-Europe 2009 (Vienna), the 5th Annual Burrill Personalised Medicine Meeting (San Francisco), and the International Congress on Genetics and Genomics at the American Heart Association meeting (Orlando), and in December, Genesis 2009 (London).
Pharmacogenetics is the study of how our genetic make-up affects the way in which we metabolise and respond to drugs. As a result, it is expected to play a key role in the future of drug development and healthcare delivery as the industry faces increasing pressure to replenish its pipeline and improve drug safety. By combining its access to genetic expertise with strategic advice on the application of pharmacogenetics in drug development, London Genetics can help companies meet this need for smarter and more efficient drug development. Given the genetic resources of its founding partners, London Genetics has broad therapeutic experience with a focus on cardiovascular drugs and cardiovascular safety.